Alobresib Uses, Dosage, Side Effects and more
Alobresib is under investigation in clinical trial NCT02607228 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer).
| Attribute | Details |
|---|---|
| Trade Name | Alobresib |
| Generic | Alobresib |
| Alobresib Other Names | Alobresib |
| Type | |
| Formula | C26H23N5O2 |
| Weight | Average: 437.503 Monoisotopic: 437.185175001 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
